The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...

The FDA has approved a label update for axicabtagene ciloleucel (axi-cel; Yescarta), a CD19-directed autologous T-cell immunotherapy. This update removes previous Limitations of Use for patients with ...

It is the first CAR-T that the agency has said is safe for this hard-to-treat subset of lymphoma patients based on data from an investigator-initiated study.

Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group.

The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Yescarta (axicabtagene ...

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the ...

The risk for central nervous system (CNS) involvement is small in cases of diffuse large B-cell lymphoma (DLBCL) because only about 5% of patients develop it. But certain high-risk patients are even ...

EB103 utilizes Eureka’s ARTEMIS technology, a platform designed to harness the human immune system more effectively than standard therapies. The ARTEMIS T cells are engineered to address the specific ...

A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully diagnosed ...

Primary central nervous system lymphoma (PCNSL) is an aggressive diffuse large B-cell lymphoma confined to the brain, spinal cord, leptomeninges and eyes. Its pathogenesis is complex, involving ...

Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective ...